Xylem XYL has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 4 | 2 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 1 | 0 | 0 |
| 2M Ago | 0 | 1 | 0 | 0 | 0 |
| 3M Ago | 1 | 1 | 1 | 0 | 0 |
Analysts have set 12-month price targets for Xylem, revealing an average target of $142.86, a high estimate of $150.00, and a low estimate of $126.00. Surpassing the previous average price target of $133.00, the current average has increased by 7.41%.
Understanding Analyst Ratings: A Comprehensive Breakdown
The analysis of recent analyst actions sheds light on the perception of Xylem by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Bryan Blair | Oppenheimer | Raises | Outperform | $142.00 | $133.00 |
| Andrew Kaplowitz | Citigroup | Raises | Neutral | $139.00 | $126.00 |
| Michael Halloran | Baird | Raises | Outperform | $148.00 | $141.00 |
| Andrew Buscaglia | Exane BNP Paribas | Announces | Outperform | $150.00 | - |
| Nathan Jones | Stifel | Raises | Buy | $150.00 | $136.00 |
| Andrew Kaplowitz | Citigroup | Raises | Neutral | $126.00 | $122.00 |
| Deane Dray | RBC Capital | Raises | Outperform | $145.00 | $140.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Xylem. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Xylem compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Xylem's stock. This examination reveals shifts in analysts' expectations over time.
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Xylem's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Xylem analyst ratings.
Discovering Xylem: A Closer Look
Xylem Inc is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $7.4 billion in revenue in 2023.
Xylem: Delving into Financials
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Positive Revenue Trend: Examining Xylem's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 40.64% as of 31 December, 2023, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 12.56%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Xylem's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.65%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Xylem's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 1.66%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Xylem's debt-to-equity ratio is below the industry average at 0.24, reflecting a lower dependency on debt financing and a more conservative financial approach.
The Core of Analyst Ratings: What Every Investor Should Know
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
